Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2022

View Archived Issues

rs41423247 SNP in NR3C1 gene predicts pneumonia complications in COVID-19

Novel vaccine candidates presented for Lassa fever

Merck & Co. patents orexin OX2 receptor agonists

Denali Therapeutics divulges new LRP3 inflammasome inhibitors

Dunad Therapeutics and collaborators present new GTPase KRAS inhibitors

Merck & Co. identifies new FXIa and/or KLKB1 inhibitors

U.S. researchers divulge new compounds for SARS-CoV-2 infection

Novel GLP-1 receptor agonist with improved oral bioavailability

Variants in the PABP-domain of PABPC1 associated with developmental delay

Genetic variants found in SLC35B2 gene tied to chondrodysplasia with hypomyelinating leukodystrophy

OliX subsidiary mCureX partners with Samyang and GC Pharma to advance mRNA vaccines

Vipergen enters derma drug discovery partnership with LEO Pharma

Lassen presents preclinical data on LASN-01 in preclinical models of skin fibrosis

Aqemia and Sanofi extend collaboration to use AI technology to optimize molecules to treat cancer

Nordic Bioscience and Roche strengthen biomarker collaboration

T cell-targeted vaccine for Coxiella burnetii infection shows promise in animal models

Blood vessel shape predicts what shape the heart is in

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...